Loading organizations...

Quentis Therapeutics is a technology company.
Quentis Therapeutics develops first-in-class cancer immunotherapies designed to modulate endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. The company’s approach translates novel biological insights into therapeutic strategies aimed at enhancing the body's immune response against cancer. This innovative methodology seeks to disarm cancer's ability to evade immune surveillance by targeting a fundamental cellular stress mechanism.
The company was founded in 2015 by Laurie Glimcher, M.D., and Juan Cubillos-Ruiz, Ph.D. Their foundational research, originating from Weill Cornell Medicine, revealed critical roles that the ER stress response plays in modulating tumor immunology. Dr. Glimcher, a distinguished immunologist, previously served as Dean of Weill Cornell Medicine, while Dr. Cubillos-Ruiz is a recognized expert in tumor immunology. Their collective work provided the key insight that launched Quentis Therapeutics.
Quentis Therapeutics aims to bring forward novel therapeutics that harness the immune system to combat various cancers. By developing drugs that specifically target ER stress pathways, the company envisions providing new treatment options for patients whose cancers currently resist standard immunotherapies. Its long-term vision is to broaden the population of cancer patients who can benefit from effective, durable immune-mediated tumor regression.
Quentis Therapeutics has raised $48.0M across 1 funding round.
Quentis Therapeutics has raised $48.0M in total across 1 funding round.
Quentis Therapeutics has raised $48.0M in total across 1 funding round.
Quentis Therapeutics's investors include Amy Schulman, Carlo Rizzuto, Polaris Partners, AbbVie Ventures, Alexandria Venture Investments, New York Ventures, Taiho Ventures, Yonghua Capital.
Quentis Therapeutics is a preclinical-stage biotechnology company developing first-in-class modulators of the endoplasmic reticulum (ER) stress response to enhance immunotherapy efficacy against cancer.[1][2][4] The company targets ER stress biology in the tumor microenvironment, with its lead program being an IRE1α inhibitor, and pursues additional targets in oncology and other ER stress-related diseases; it serves cancer patients by boosting the immune system's anti-tumor activity.[1][4] Founded in 2016 and headquartered in New York, NY, Quentis raised $48 million in a Series A round in 2018 from investors including Versant Ventures, Polaris Partners, AbbVie Biotech Ventures, and others, though its current status appears archived with limited recent public activity or revenue reported around $3 million.[1][3][5]
Quentis Therapeutics was founded in 2016, leveraging deep expertise in ER stress biology to translate novel insights into therapeutics.[1][5] The company's emergence stemmed from recognizing ER stress pathways' role in the tumor microenvironment, particularly how they limit immunotherapy benefits for cancer patients; this led to pioneering IRE1α inhibitors and other modulators.[1][4] Early traction came swiftly with a $48 million Series A financing in February 2018, backed by prominent biotech investors like Versant Ventures and Polaris Partners, validating its preclinical immuno-oncology approach.[1]
Quentis rides the immuno-oncology wave, where ER stress modulation addresses key resistance mechanisms in the tumor microenvironment, a critical trend as immunotherapy expands beyond initial responders.[1][4] Timing aligns with post-2018 advances in checkpoint inhibitors and combination therapies, where microenvironment-targeted agents like IRE1α inhibitors could unlock broader patient benefits amid a market projected to grow significantly in precision oncology.[1] Favorable forces include surging VC interest in biotech (evident in its Series A) and rising focus on ER stress in diseases, influencing the ecosystem by pioneering pathway-specific immunomodulators that could integrate with existing standards.[1][2]
Quentis' archived status suggests potential acquisition, wind-down, or pivot since its 2018 funding, with no recent public milestones amid a competitive immuno-oncology field.[5] Next steps likely involve advancing preclinical assets toward IND filings or partnerships, shaped by trends like AI-driven target discovery and multi-modal therapies enhancing ER stress modulation. Its influence could evolve through licensing its platform, contributing to next-gen cancer treatments that tie back to its core mission of expanding immunotherapy access.[1][4]
Quentis Therapeutics has raised $48.0M across 1 funding round. Most recently, it raised $48.0M Series A in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $48.0M Series A | Amy Schulman, Carlo Rizzuto | Polaris Partners, AbbVie Ventures, Alexandria Venture Investments, New York Ventures, Taiho Ventures, Yonghua Capital |